Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoricoxib/Cyclobenzaprine FDC for Muscle Spasm After Third Molar Extraction
NCT05683574Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of etoricoxib, cyclobenzaprine in Muscle spasm, acute pain, sponsored by Eurofarma. Planned start May 2026; status: withdrawn.
02
Drugs
etoricoxibcyclobenzaprine
03
Conditions
Muscle spasmacute pain
Beyond the preview
Go deeper on NCT05683574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683574.